Trials / Unknown
UnknownNCT01683175
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | |
| DRUG | cis-platinum | |
| DRUG | Vinorelbine |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2012-09-11
- Last updated
- 2016-10-20
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01683175. Inclusion in this directory is not an endorsement.